TT 373
Alternative Names: TT-373Latest Information Update: 30 Jun 2022
At a glance
- Originator Teon Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Carrier protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Jun 2022 Preclinical trials in Solid tumours in USA (unspecified route) (Teon Therapeutics pipeline, June 2022)